Jill M. Broadfoot
2018 - aTYR PHARMA
In 2018, Jill M. Broadfoot earned a total compensation of $334.1K as Chief Financial Officer at aTYR PHARMA.
Compensation breakdown
| Non-Equity Incentive Plan | $58,324 |
|---|---|
| Option Awards | $121,880 |
| Salary | $148,526 |
| Other | $5,393 |
| Total | $334,123 |
Broadfoot received $148.5K in salary, accounting for 44% of the total pay in 2018.
Broadfoot also received $58.3K in non-equity incentive plan, $121.9K in option awards and $5.4K in other compensation.
Rankings
In 2018, Jill M. Broadfoot's compensation ranked 12,952nd out of 14,244 executives tracked by ExecPay. In other words, Broadfoot earned more than 9.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,952 out of 14,244 | 9th |
Division Manufacturing | 5,246 out of 5,765 | 9th |
Major group Chemicals And Allied Products | 1,969 out of 2,128 | 8th |
Industry group Drugs | 1,689 out of 1,817 | 7th |
Industry Biological Products, Except Diagnostic Substances | 325 out of 339 | 4th |
Source: SEC filing on March 28, 2019.
Broadfoot's colleagues
We found three more compensation records of executives who worked with Jill M. Broadfoot at aTYR PHARMA in 2018.
News
aTYR PHARMA CEO Sanjay Shukla's 2023 pay falls 46% to $1.3M
April 5, 2024
aTYR PHARMA CEO Sanjay Shukla's 2021 pay jumps 75% to $1.9M
March 22, 2022
aTYR PHARMA CEO Sanjay Shukla's 2020 pay jumps 63% to $1.1M
March 23, 2021
aTYR PHARMA CEO Sanjay Shukla's 2019 pay falls 52% to $664K
April 2, 2020
aTYR PHARMA CEO Sanjay Shukla's 2018 pay falls 36% to $1.4M
March 28, 2019